Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Clinical and Translational Science · 2026-10 · 19 (10)
DOI: 10.1111/cts.70732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 23.09.2026. Verfasst von Rune Aabjerg Nørgaard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Development ADME, Novo Nordisk A/S, Måløv, Denmark. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Prescription Drugs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development ADME, Novo Nordisk A/S, Måløv, Denmark.
- Targeted Learning and Causal Inference, Novo Nordisk A/S, Søborg, Denmark.
- Corporate Affairs and Communication, Rare Disease, Novo Nordisk, Zurich, Switzerland.
ORCID-Profile: Rune Aabjerg Nørgaard, Laura Grenier, Peter Bruun-Rasmussen, Carolina Säll
Zitieren
APA
Nørgaard, R. A., Grenier, L., Bruun-Rasmussen, P., Osunkwo, I., & Säll, C. (2026). Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States. Clinical and Translational Science, 19(10). https://doi.org/10.1111/cts.70732
Vancouver
Nørgaard RA, Grenier L, Bruun-Rasmussen P, Osunkwo I, Säll C. Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States. Clinical and Translational Science. 2026;19(10). doi:10.1111/cts.70732
BibTeX
@article{Nrgaard2026,
author = {Nørgaard, Rune Aabjerg and Grenier, Laura and Bruun-Rasmussen, Peter and Osunkwo, Ifeyinwa and Säll, Carolina},
title = {Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {10},
doi = {10.1111/cts.70732}
}
EUVIMED